Brinsupri™

Drugs - Brinsupri™ (brensocatib) [Insmed Incorporated]

May 2026

Therapeutic area - DPP1 inhibitor

Initial approval criteria

• Age ≥ 12 years; AND
• Patient has a diagnosis of bronchiectasis and ALL of the following:
  • Patient has a clinical history consistent with bronchiectasis (e.g., cough, chronic sputum production, recurrent respiratory infections); AND
  • Patient has had computed tomography (CT) to confirm the diagnosis of bronchiectasis; AND
  • Patient does NOT have cystic fibrosis, primary or secondary immunodeficiency, non-tuberculous mycobacterial (NTM) disease, allergic bronchopulmonary aspergillosis (ABPA) or tuberculosis; AND
  • Patient has had at least one pulmonary exacerbations that required an antibiotic prescription within the last 12 months; AND
• The prescriber is a specialist in the area of the patient’s diagnosis (e.g., pulmonologist) or the prescriber has consulted with a specialist in the area of the patient’s diagnosis.

Renewal criteria

• Patient must continue to meet the above criteria; AND
• Patient has had clinical benefit with treatment (e.g., reduced rate of pulmonary exacerbations); AND
• Patient has NOT experienced any treatment-restricting adverse effects.

Quantity limits

• 30 tablets per 30 days

Questions?

Provider Call Center: (844) 575-7887